History of Breastfeeding Associated with Reduced Risk of Breast Cancer Recurrence
OAKLAND, Calif. — Women diagnosed with breast cancer who previously breastfed their babies had a 30 percent overall decreased risk of the disease recurring, according to a new Kaiser
Permanente study published in the Journal of the National Cancer Institute. In addition, researchers found that the protective effect of breastfeeding was more pronounced for tumors of particular genetic subtypes, including the most commonly diagnosed of all breast cancers.The study involved 1,636 women with breast cancer who completed a questionnaire that included breastfeeding history. Additional medical data were obtained from medical chart reviews and Kaiser Permanente HealthConnect®, a comprehensive electronic health record.“This is the first study we’re aware of that examined the role of breastfeeding history in cancer recurrence, and by tumor subtype,” said Marilyn L. Kwan, PhD, research scientist with the Kaiser Permanente Division of Research and lead author of the study.The researchers found there to be benefits of breastfeeding on expected outcomes among women who were diagnosed with the luminal A subtype of breast cancer, while no significant associations were observed for those with other subtypes. Luminal A tumors include the estrogen-receptor positive (or ER+) breast tumors, which are the most commonly diagnosed of all breast cancers. These tumors are less likely to metastasize, are treatable with hormonal therapy such as tamoxifen and aromatase inhibitors, and generally have better outcomes.
In addition to decreased risk of breast cancer recurrence, women who breastfed were also 28 percent less likely to die from the disease.
There are a number of possible explanations for why breastfeeding could be associated with a better prognosis once a woman is diagnosed with breast cancer.
“Women who breastfeed are more likely to get the luminal A subtype of breast cancer, which is less aggressive, and breastfeeding may set up a molecular environment that makes the tumor more responsive to anti-estrogen therapy,” Kwan said.
Click HERE for the rest of the article